Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Latest Information Update: 12 Mar 2021
At a glance
- Drugs Temtokibart (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors LEO Pharma
Most Recent Events
- 10 Mar 2021 Status changed from active, no longer recruiting to completed.
- 17 Feb 2021 Planned End Date changed from 1 Jan 2021 to 12 May 2021.
- 17 Feb 2021 Planned primary completion date changed from 1 Jan 2021 to 12 May 2021.